Related Experiment Videos
[Safety profile of 311C90 (zolmitriptan)]
1Servicio de Neurología, Hospital Clínico Universitario, Zaragoza.
Neurologia (Barcelona, Spain)
|December 22, 1998
Summary
Zolmitriptan, a selective 5HT1B/1D receptor agonist, demonstrates a favorable safety profile in migraine patients and healthy volunteers. The 2.5 mg dose offers the best benefit-risk balance, with mild, transient side effects.
Area of Science:
- Pharmacology
- Clinical Trials
- Migraine Treatment
Context:
- Zolmitriptan (311C90) is a selective 5HT1B/1D receptor agonist.
- Migraine treatment necessitates understanding drug safety and efficacy.
- Extensive clinical trials inform the safety profile of new migraine therapies.
Purpose:
- To conduct a bibliographic review of zolmitriptan's safety profile.
- To evaluate the influence of zolmitriptan on cardiovascular parameters.
- To assess the tolerability and adverse effects of zolmitriptan in diverse populations.
Summary:
- Zolmitriptan showed no significant impact on arterial pressure or ECG parameters in healthy volunteers and migraine patients.
- Long-term use did not result in changes in hemogram or biochemical markers.
- Most frequent side effects included nausea and dizziness, generally mild and transient.
Impact:
- Zolmitriptan is well-tolerated across a wide patient spectrum.
- The 2.5 mg dosage appears optimal for balancing benefits and risks.
- Caution is advised when co-administering zolmitriptan with MAO-A inhibitors due to potential pharmacokinetic interactions.